Fortrea Holdings Inc. (FTRE) vs Intellia Therapeutics, Inc. (NTLA)
A side-by-side comparison of Fortrea Holdings Inc. and Intellia Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
FTRE
Fortrea Holdings Inc.
$20.00HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
NTLA
Intellia Therapeutics, Inc.
$12.26HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — FTRE vs NTLA
growth of $100 · dividends reinvested · last 3yFTRE -37.5% (-14.5%/yr)NTLA -71.9% (-34.5%/yr)FTRE compounded faster over this window
FTRE NTLA
FTRE vs NTLA: by the numbers
- •FTRE is the larger company ($1.90B vs $1.71B market cap).
- •Both run net losses; FTRE's is the smaller (-3.18% vs -672.16% net margin).
- •NTLA grew revenue faster over the past five years (7.31% vs 1.09% CAGR).
Metrics side by side
Valuation
| Metric | FTRE | NTLA |
|---|---|---|
| Forward P/E | 23.78 | N/A |
| P/S ratio | 0.71 | 28.79 |
| P/B ratio | 3.63 | 2.35 |
| EV / EBITDA | 31.92 | N/A |
| FCF yield | 7.92% | N/A |
Profitability
| Metric | FTRE | NTLA |
|---|---|---|
| Gross margin | 17.11% | 76.47% |
| Operating margin | 0.41% | -651.67% |
| Net margin | -3.18% | -672.16% |
| ROE | -16.25% | -54.96% |
| ROIC | 0.62% | -54.45% |
Growth (annualized)
| Metric | FTRE | NTLA |
|---|---|---|
| Revenue CAGR (5Y) | 1.09% | 7.31% |
| FCF CAGR (5Y) | -12.98% | N/A |
| Total return CAGR (5Y) | N/A | -38.01% |
Frequently asked
- Which has grown faster, FTRE or NTLA?
- Over the past five years, NTLA grew revenue faster — FTRE at a 1.09% CAGR versus NTLA at 7.31%.
Go deeper
Dig into the metrics
Fortrea ROEIntellia Therapeutics ROEFortrea operating marginIntellia Therapeutics operating marginFortrea revenue growthIntellia Therapeutics revenue growthFortrea free cash flowIntellia Therapeutics free cash flow
Fortrea & Intellia Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.